Is there a place for different isoforms of FSH in clinical medicine?: IV. The clinician's point of view | Zendy

D. T. Baird | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Is there a place for different isoforms of FSH in clinical medicine?: IV. The clinician's point of view

Author(s) -

D. T. Baird

Publication year - 2001

Publication title -

human reproduction

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.446

H-Index - 226

eISSN - 1460-2350

pISSN - 0268-1161

DOI - 10.1093/humrep/16.7.1316

Subject(s) - hypogonadotrophic hypogonadism , infertility , gametogenesis , spermatogenesis , follicle stimulating hormone , medicine , endocrinology , gene isoform , follicle , anovulation , oogenesis , biology , hormone , andrology , gynecology , pregnancy , oocyte , luteinizing hormone , microbiology and biotechnology , genetics , insulin , embryo , insulin resistance , lactation , polycystic ovary , gene

Follicle stimulating hormone (FSH) plays an important role in gametogenesis in both men and women. In men it is required for the establishment and probably maintenance of spermatogenesis. In women it stimulates the growth of ovarian follicles and fluctuations in its secretion are involved in the selection of the ovulatory follicle. It is now possible by recombinant DNA technology to synthesize a range of isoforms of FSH with differing biological action and half-life which would provide a greater degree of flexibility in the treatment of women with anovulatory infertility. Longer acting isoforms of FSH would find clinical application in the treatment of hypogonadotrophic men.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research